TEL AVIV, Israel, Nov. 28, 2016 -- Elbit Imaging Ltd. (the "Company") (TASE:EMITF) (NASDAQ:EMITF) announced today, in furtherance to its announcement dated March 17, 2016, regarding the proposal from its subsidiary, Elbit Medical Technologies Ltd. (“Elbit Medical”) to convert all the outstanding debts of Elbit Medical to the Company (the "Proposal"), which as of today amount to approximately NIS 150.24 million ($38.82) ("Elbit Medical's Debt"), that the Company's board of directors has decided to reject the Proposal.
In addition, the Company's board of directors has accepted Elbit Medical's request to extend the maturity date of Elbit Medical's Debt to the Company such that the new maturity date of all Elbit Medical’s Debt to the Company shall be April 1, 2018.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotel - operation and management of the Radisson hotel Complex in Bucharest, Romania. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2015, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]


Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 



